Breathe Well Live Well
|
Pediatric Asthma Research Gets NIH Grant Funding
Pharmacy Times The National Institutes of Health (NIH) has awarded universities about $28 million in grants to study pediatric asthma triggers. Thanks to the grants, researchers will be able to develop wearable and non-wearable sensors that track pediatric … |
View full post on asthma – Google News
Laredo Morning Times |
School district gets grant to help treat students with asthma
Laredo Morning Times United ISD was the beneficiary of a grant from the Laredo Diploma Plus Foundation. The nonprofit organization gave United ISD a grant to purchase nebulizers that will be given to each campus to treat students with asthma. Pictured, from left, at a … |
View full post on asthma – Google News
NDTV |
Unichem Gets USFDA Nod for Generic Asthma Treatment Tablets
NDTV New Delhi: Drug firm Unichem Laboratories has received approval from the US health regulator for its Montelukast Sodium tablets used in prevention and chronic treatment of asthma. "The company has received ANDA approval for Motelukast Sodium tablets … |
View full post on asthma – Google News
|
BRIEF-GSK gets European regulators approval for biotech asthma drug
Reuters Sept 24 GlaxoSmithkline Plc. * Receives positive CHMP opinion in Europe for novel anti-IL5 biological nucala for treatment of patients with severe refractory eosinophilic asthma. * Decision is based on results from clinical study programme, which … |
View full post on asthma – Google News
European Pharmaceutical Review |
Spiriva Respimat (Tiotropium) Gets Asthma Indication in US
Medscape The US Food and Drug Administration (FDA) has approved the long-acting muscarinic antagonist tiotropium bromide (Spiriva Respimat, Boehringer Ingelheim) for long-term maintenance treatment of asthma in people aged 12 years and older, according to a … FDA approves Boehringer's asthma treatment FDA approves asthma treatment Spiriva Respimat |
View full post on asthma – Google News
|
GSK Gets Canadian Approval For BREO ELLIPTA For Treatment Of Asthma In Adults
Nasdaq BREO® ELLIPTA is a fixed-dose combination of the inhaled corticosteroid fluticasone furoate and the long-acting beta2-agonist vilanterol. Two strengths, 100/25 mcg and 200/25 mcg, have been approved in Canada for use in asthma. BREO is administered … GSK-Theravance's Breo Ellipta gets Canadian approval to treat asthma in adults GSK Receives Approval for BREO(R) ELLIPTA(R) for the Treatment of Adults With … |
View full post on asthma – Google News
|
GSK Gets Canadian Approval for BREO ELLIPTA for Treatment of Asthma in Adults
RTT News GlaxoSmithKline plc (GSK) and Theravance, Inc. (THRX) on Thursday announced the approval in Canada of BREO ELLIPTA for the once-daily maintenance treatment of asthma in patients aged 18 years and older with reversible obstructive airways disease. GSK Receives Approval for BREO(R) ELLIPTA(R) for the Treatment of Adults With … |
View full post on asthma – Google News
|
Ajanta Pharma gets USFDA nod for generic asthma treatment drug
Economic Times NEW DELHI: Drug firm Ajanta Pharma has received final approvals from the US health regulator for generic montelukast tablets and oral granules used for prevention and treatment of asthma and to relieve symptoms of seasonal hay fever. The company has … |
View full post on asthma – Google News
|
Man gets 6 to 8 years for manslaughter
Boston Globe A Boston man received a prison sentence of six to eight years on Friday for a 2012 incident in which he fired a gun on a city street, causing another man to flee and die of an asthma attack, Suffolk District Attorney Daniel F. Conley's office said … |
View full post on asthma – Google News
Medscape |
GlaxoSmithKline's new asthma drug gets a split vote from FDA advisers
FierceBiotech GSK's injection, mepolizumab, works by blocking the protein interleukin-5 to prevent buildups of white blood cells in the lungs that can exacerbate asthma. The company is angling to get the drug approved as a treatment for sufferers of severe asthma … FDA Panel Backs Mepolizumab for Severe Eosinophilic Asthma GlaxoSmithKline plc (ADR) Wins FDA Panel Backing For Severe Asthma Drug Asthma Drug Targeting IL-5 Wins Partial Backing From FDA Advisers |
View full post on asthma – Google News